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Objective. To determine the linezolid clearance and serum concentrations in
a critically ill man receiving continuous venovenous hemodiafiltration
(CVVHDF).
Methods. Intravenous linezolid 600 mg every 12 hours was administered to a
critically ill, 85-year-old man with anuria who was receiving CVVHDF at a
dialysate flow rate of 2000 ml/hour and a mean ultrafiltrate production rate
of 775 ml/hour.  Samples of blood and spent dialysate and ultrafiltrate were
obtained at the time of linezolid peaks and troughs, and linezolid
concentrations were determined.
Results. The CVVHDF yielded a mean linezolid clearance of 36.5 ml/minute
and an elimination half-life of 7.5 hours.  The linezolid saturation
coefficient ranged from 0.77–0.81.  Administration of intravenous linezolid
600 mg every 12 hours yielded suitable serum trough concentrations.
Conclusion. Administration of intravenous linezolid 600 mg every 12 hours
maintained therapeutic serum trough concentrations in this critically ill
patient receiving CVVHDF.
(Pharmacotherapy 2003;23(8):1071–1075)
The number of infections caused by gram-
positive bacteria continues to increase, with
Staphylococcus aureus,  coagulase-negative
staphylococci, and Enterococcus sp among the
most common causes of bacteremia.1
Antimicrobial resistance among these pathogens
continues to increase.  From 1994–1998,
infections caused by oxacillin-resistant S. aureus
and vancomycin-resistance Enterococcus sp have
increased 40%.2 Linezolid, a novel oxazolidinone
antimicrobial, is effective for the treatment of
infections caused by gram-positive pathogens
such as methicillin-resistant S. aureus3–7 and
vancomycin-resistant Enterococcus sp.8 With the
emergence of resistant gram-positive organisms
such as these, and most recently vancomycin-
resistant S. aureus,9, 10 linezolid becomes an
increasingly important antimicrobial agent.
In the last 12–24 months, our institution has
experienced an increase in the number of
infections caused by vancomycin-resistant
Enterococcus and methicillin-resistant Staphylo-
coccus sp that require treatment with linezolid.
Many patients with these infections have been
critically ill and required intensive care.  Six also
had kidney failure and required continuous renal
replacement therapy (CRRT).  Like many other
institutions,11 we have been providing CRRT as
treatment of acute kidney failure in intensive care
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patients.
To our knowledge, dosing recommendations
for linezolid in patients receiving CRRT have not
been published; however, some pharmacokinetic
properties of the drug have been elucidated.
Under steady-state conditions in a healthy adult,
approximately 30% of linezolid is eliminated by
way of the kidneys as the parent drug and 50% as
carboxylic acid metabolites.12 Although linezolid
clearance is reduced with decreased renal
function, total clearance remains constant in
patients with minimal renal function.13 During
intermittent hemodialysis, linezolid clearance is
increased by approximately 80%.12 Approxi-
mately 30% of a linezolid dose is removed in a 3-
hour hemodialysis session.12 One study reported
a dialysis extraction ratio of 38% that remained
constant throughout the dialysis session.13
However, the elimination rate constant did not
change, and the authors concluded that no
linezolid dosing adjustment is necessary in
patients receiving intermittent hemodialysis.13
Given that linezolid is removed by intermittent
hemodialysis and has a small molecular weight
(337 daltons), it is possible that a significant
amount of linezolid is removed during CRRT,
which provides renal replacement therapy 24
hours/day.  Inappropriate dosing could result in
subtherapeutic serum concentrations and
therapeutic failure.
We describe a patient receiving linezolid and
continuous venovenous hemodiafiltration
(CVVHDF) who did not appear to be responding
to linezolid therapy.  Consequently, steady-state
serum and dialysate linezolid concentrations
were determined to assess whether adequate
linezolid concentrations were being achieved and
to determine CVVHDF linezolid clearance.
Case Report
An 85-year-old man with a history significant
for hypertension, coronary artery disease, atrial
fibrillation, chronic obstructive pulmonary
disease, peripheral vascular disease, peptic ulcer
disease, osteoarthritis, and a cerebrovascular
accident was admitted to the hospital for repair
of an abdominal aortic aneurysm and right renal
artery reimplantation.  The patient had a
prolonged hospital course complicated by
ischemic colitis, intraabdominal infection, sepsis,
respiratory failure requiring prolonged
mechanical ventilation, and acute renal failure.
He also underwent several colonoscopies,
exploratory laparotomies, and a total colectomy.
In addition, he was receiving broad-spectrum
antibiotic therapy with vancomycin, metro-
nidazole, and levofloxacin throughout his
hospital stay.  Thirteen days after his surgery, a
peritoneal fluid culture revealed vancomycin-
resistant E. faecium sensitive to linezolid, as
determined by the Kirby-Bauer disk diffusion
method.  Subsequently, vancomycin was replaced
with intravenous linezolid 600 mg every 12
hours.
A second peritoneal fluid sample was obtained
and sent for culture and sensitivities on
postoperative day 24.  This culture also grew
vancomycin-resistant Enterococcus sp sensitive to
linezolid.  On postoperative day 27, CVVHDF
was started for volume control.  At this point, the
patient’s weight was 100.1 kg (dry weight
approximately 80 kg), serum albumin 2.8 g/dl,
and hematocrit 30.2%.  His recovery continued
to be slow, and he did not appear to be
responding to therapy.  Serum and combined
dialysate-ultrafiltrate (effluent) samples were
obtained and linezolid content assayed to ensure
appropriate linezolid dosing during CVVHDF.
The patient was receiving the following drugs on
the day the samples were obtained:  hydralazine
20 mg every 8 hours via nasogastric tube,
isosorbide dinitrate 20 mg 3 times/day via
nasogastric tube; intravenous digoxin 0.25 mg
every 48 hours, intravenous linezolid 600 mg
every 12 hours, intravenous levofloxacin 500 mg
every 48 hours, intravenous metronidazole 500
mg every 8 hours, intravenous doxycycline 100
mg every 12 hours, continuous intravenous
infusion of propofol titrated to effect; subcu-
taneous enoxaparin 40 mg/day; and total
parenteral nutrition with 20% fat emulsion daily.
The patient received CVVHDF for 23 days,
during which time he had anuria.  Several days
after linezolid samples were obtained, his clinical
course continued to worsen, and he required
high-dose vasopressor support.  Eventually, the
patient’s family and physicians agreed to remove
life-support therapy, and he died 50 days after his
surgery.
Methods
Continuous Venovenous Hemodiafiltration
Continuous venovenous hemodiafiltration was
accomplished using a CRRT machine (Diapact, B.
Braun, Bethlehem, PA).  A polysulfone
hemodiafilter (F70 NR, Fresenius Medical Care
North America, Lexington, MA) (ultrafiltration
coefficient 49 ml/hr/mm Hg, surface area 1.6 m2)
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was used throughout the treatment.  Descriptions
and properties of various methods of CRRT, such
as CVVHDF, have been described.14 The blood
flow rate was maintained at 200 ml/minute
throughout the treatment period.  The dialysate
flow rate was maintained at 33.3 ml/minute; the
ultrafiltrate production rate was varied from
11.2–14.5 ml/minute (mean 12.9 ml/min) to
meet fluid removal goals and maintain the
patient’s blood pressure level.
The dialysate used was a custom-made solution
containing sodium 135 mEq/L, potassium 3
mEq/L, chloride 107 mEq/L, bicarbonate 28
mEq/L, magnesium 1 mEq/L, and glucose 100
mg/dl.  For anticoagulation, a citrate dextrose
solution (ACD, Baxter-Fenwal, Deerfield, IL) was
used.  Anticoagulation was reversed using
calcium chloride infused in a central venous
catheter not connected to the CRRT circuit.
Blood samples were obtained from extracorporeal
blood access sites prefilter (A) and postfilter (V).
Effluent from the hemofilter containing a
combination of spent dialysate (D) and ultra-
filtrate (F) were obtained simultaneously from
the dialysate side sampling port.  All blood and
effluent samples were obtained 15 minutes before
the dose was administered (trough 1), and 30
minutes after the end of a 1-hour infusion (peak)
and again at the end of the dosing interval,
approximately 12 hours later (trough 2).
Calculations
Standard equations were used to calculate
pharmacokinetic properties of half-life,
elimination rate, and volume of distribution (Vd).
The saturation coefficient was calculated using
the standard formula:
SA = CE/Cp, Cp = (CA + CV)/2
where SA is the saturation coefficient, CE is the
concentration in the effluent, Cp is the linezolid
concentration in the plasma, CA is the linezolid
concentration in the plasma drawn from the
prefilter sampling port, and CV is the linezolid
concentration in the plasma drawn from the
postfilter sampling port.
Total body clearance was calculated as:
Dose/AUC0–∞
where AUC0–∞ is the area under the
concentration versus the time curve.
The clearance from CRRT was calculated as:
ClCRRT = (QD + QF) • SA
where ClCRRT is clearance from CRRT, QD is the
dialysate flow rate, and QF is the ultrafiltrate
production rate.
Assay Methodology
Serum concentrations of linezolid were
determined using a validated high-performance
liquid chromatography (HPLC) assay.15 Samples
were measured using a system consisting of a
Waters 515 HPLC pump (Waters, Milford, MA)
with a Waters model 680 gradient controller and
a solvent select valve, a Spectra Physics model
8875 fixed-volume autosampler (Spectra Physics,
San Jose, CA), a Waters model 486 ultraviolet
detector, a Macintosh 7100 computer (Apple
Computers Inc., Cupertino, CA), and the Rainin
Dynamax HPLC data management system
(Rainin, Woburn, MA).  The plasma standard
curve for linezolid ranged from 0.5–30 mg/ml;
absolute recovery of linezolid from plasma was
95%.  The within-sample precision (percent
coefficient of variation) of validation of a single
standard concentration was 0.69%, and the
overall validation precision across all standards
was 1.04–4.39%.  The lower detection limit of
the assay was 0.5 µg/ml.
Results
Blood and effluent samples were obtained as
planned for the two trough values.  However, for
the peak values, only the ultrafiltrate and the A
blood sample were obtained correctly.  The V
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Table 1.  Peak and Trough Linezolid Concentrations in a Critically Ill Patient Receiving
Continuous Venovenous Hemodiafiltration
Parameter Trough 1 Peak Trough 2
Prefilter blood sample 7.2 µg/ml 16.4 µg/ml 6.2 µg/ml
Postfilter blood sample 7.2 µg/ml ND 6.1 µg/ml
Effluent sample 5.6 µg/ml 13.6 µg/ml 5.0 µg/ml
Time since end of previous dose infusion 9.38 hrs 0.5 hrs 12.0 hrs
Calculated saturation coefficient 0.77 ND 0.81
ND = not done.
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sample was not obtained from the postfilter
venous site.  Instead, the nurse took a sample
from a central venous site not connected to the
CRRT circuit.  Consequently, a saturation
coefficient was not calculated for the linezolid
peak.  Blood and effluent concentrations are
shown in Table 1.
While the patient was receiving CVVHDF, his
calculated linezolid Vd was approximately 49 L,
total body clearance 84.7 ml/minute, and half-life
approximately 7.5 hours.  The saturation
coefficient ranged from 0.77–0.81 at the troughs.
Using the mean of these two saturation
coefficient values, ClCRRT was calculated to be
36.5 ml/minute; mean effluent flow rate was 46.2
ml/minute.
Discussion
Linezolid is bacteriostatic against most gram-
positive aerobic bacteria, but it displays
bactericidal activity against some strains of
Streptococcus pneumoniae.12, 16, 17 Breakpoint
concentrations for linezolid against Enterococcus
and Streptococcus sp indicate that susceptible
organisms have a minimum inhibitory
concentration (MIC) of 2 µg/ml or less, whereas
susceptible Staphylococcus sp have an MIC of 4
µg/ml or less.12 Breakpoints for other gram-
positive pathogens are not established.
The reported linezolid elimination half-life is
4.5–5.5 hours in patients with normal renal
function.12 Linezolid has a steady-state Vd of
about 40–50 L and is 31% bound to plasma
protein.12 The recommended dosage for these
patients is either oral or intravenous linezolid
600 mg every 12 hours.  Linezolid pharmaco-
kinetics are not significantly altered, and dosage
adjustments are unnecessary for patients with
renal insufficiency12; however, it is recommended
that linezolid be administered after hemo-
dialysis.12, 13 Reports of linezolid disposition in
patients receiving CRRT have appeared, to our
knowledge, in only one published abstract.18
We obtained these serum and effluent linezolid
values in our patient to ensure that his serum
trough concentrations were therapeutic and to
determine the extent of linezolid clearance by
CVVHDF.  Animal data suggest that the major
pharmacodynamic parameter that determines
efficacy of linezolid is the time that the drug
concentration remains above the MIC for the
pathogen.17 Therefore, serum linezolid
concentration should be maintained at or above
the MIC for most of the dosing interval.  In our
patient, trough serum concentrations achieved
with intravenous linezolid 600 mg every 12
hours were 7.2 and 6.1 µg/ml, well above the
previously reported MICs.12 In our patient, the
peak and trough serum concentrations achieved
with this dosing regimen also are similar to
previous reports with repeated 600-mg
intravenous and oral doses.12
In patients receiving continuous hemofiltration,
the sieving coefficient is used in calculating drug
clearance.  In our patient, continuous hemodia-
filtration was administered, and effluent flowing
from the dialysate out port contains both spent
dialysate and ultrafiltrate.  Consequently,
measuring linezolid content in effluent cannot be
used to distinguish how much drug appears in
the effluent because of dialysis and how much
because of hemofiltration.  The CE:Cp ratio yields
the saturation coefficient, which is probably very
close to the sieving coefficient at low dialysate
flow rates.19, 20 The saturation coefficient of
linezolid we observed (0.77–0.81) is similar to
that of the reported nonprotein bound fraction of
linezolid.
In patients with normal renal function,
linezolid plasma protein binding is
approximately 31%.12 In critically ill patients (or
those with renal failure) the extent of protein
binding is unknown.  Some experts suggest that
the unbound fraction of a drug can be used as a
sieving coefficient when the sieving coefficient is
unknown.14, 19, 21 Regarding linezolid, it appears
that this literature-derived estimate (~0.7)
provides a reasonable estimate of the saturation
coefficient, and consequently, the sieving
coefficient.  However, we did not assess actual
linezolid plasma protein binding in our patient.
The outflow from the dialysate side of the
hemofilter was 33.3 ml/minute dialysate flow
plus a mean of 12.9 ml/minute of ultrafiltrate
flow.  This ultrafiltrate production was necessary
to remove the 5-ml/minute citrate solution used
as an anticoagulant, to provide adequate fluid
removal for the obligate fluid intake due to
nutrition and intravenous drugs, and to provide
adequate volume removal in our patient, who
was overloaded with fluids.  The mean desired
net hourly fluid loss was 3.3 ml/minute for this
patient.  His ultrafiltrate production rate resulted
in more of a mixed hemodiafiltration rather than
a strict diffusional CRRT like continuous
hemodialysis.  Consequently, the calculated
clearance of 36.5 ml/minute derived from the
saturation coefficient values results from both
diffusive and convective drug clearance.  In
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patients with normal renal function, total drug
clearance ranges from 80–146 ml/minute, with
renal clearance accounting for 40 ml/minute, or
about 35–40% of total clearance.12 This is
approximately what was achieved with our CRRT
regimen, which yielded a mean effluent rate of
46.2 ml/minute.  Total body clearance in our
patient was 84.7 ml/minute, and ClCRRT was 36.5
ml/minute, meaning that CRRT yielded
approximately 43% of all clearance.
Linezolid half-life in our patient was
approximately 7.5 hours during CVVHDF,
compared with the reported elimination half-life
of about 5 hours in patients with normal renal
function.12 Linezolid half-life in patients with
renal failure is not substantially different from
that in patients with normal renal function,12, 13
that is, about 7 hours.12 The calculated linezolid
Vd in our fluid-overloaded patient was
approximately 49 L; normal Vd is 40–50 L.12
Repeated samples were not obtained after the
fluid was removed, so we were unable to
determine what effect fluid overload had on
linezolid Vd.
Conclusion
The manufacturer’s dosing recommendation of
intravenous linezolid 600 mg every 12 hours
achieved appropriate serum trough concentra-
tions in our patient, who was receiving CVVHDF
at 2–3 L/hour of dialysate and ultrafiltrate
production.  Although CVVHDF contributed
36.5 ml/minute of linezolid clearance, it was
insufficient to warrant increasing the dosage.
These findings confirm those of a preliminary
report18 that CVVHDF does not significantly
remove linezolid.
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